Literature DB >> 708470

Studies on the mode of interaction of 4'-epi-adriamycin and 4-demethoxy-daunomycin with DNA.

T W Plumbridge, J R Brown.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 708470     DOI: 10.1016/0006-2952(78)90037-0

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  8 in total

Review 1.  Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  L M Hollingshead; D Faulds
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

2.  Method for the determination of 4-demethoxydaunorubicin, its quinone and hydroquinone metabolites in human plasma and urine by high-performance liquid chromatography.

Authors:  J Cummings; R Milroy; S W Banham; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 3.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 4.  Epirubicin. Clinical pharmacology and dose-effect relationship.

Authors:  J Robert
Journal:  Drugs       Date:  1993       Impact factor: 9.546

5.  Similar changes in cardiac morphology and DNA synthesis induced by doxorubicin and 4'-epi-doxorubicin.

Authors:  K Wassermann; K Mølgaard; E Steiness
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  Anthracycline dose intensification in young adults with acute myeloid leukemia.

Authors:  Eric Padron; Hugo Fernandez
Journal:  Ther Adv Hematol       Date:  2012-02

7.  Pharmacokinetics of 4'-epi-doxorubicin in man.

Authors:  H Weenen; J Lankelma; P G Penders; J G McVie; W W ten Bokkel Huinink; M M de Planque; H M Pinedo
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

Review 8.  Clinical pharmacokinetics of epirubicin.

Authors:  J Robert
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.